193 related articles for article (PubMed ID: 26531723)
1. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.
Angioli R; Capriglione S; Scaletta G; Aloisi A; Miranda A; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2016 Apr; 37(4):4973-8. PubMed ID: 26531723
[TBL] [Abstract][Full Text] [Related]
2. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.
Capriglione S; Plotti F; Miranda A; Ricciardi R; Scaletta G; Aloisi A; Guzzo F; Montera R; Angioli R
Tumour Biol; 2015 Jun; 36(6):4151-6. PubMed ID: 25577252
[TBL] [Abstract][Full Text] [Related]
3. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
4. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
5. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
[TBL] [Abstract][Full Text] [Related]
6. Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.
Quan Q; Liao Q; Yin W; Zhou S; Gong S; Mu X
Sci Rep; 2021 Nov; 11(1):21694. PubMed ID: 34737393
[TBL] [Abstract][Full Text] [Related]
7. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
8. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
9. The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.
Abdalla N; Pazura M; Słomka A; Piórkowski R; Sawicki W; Cendrowski K
Ginekol Pol; 2016; 87(12):781-786. PubMed ID: 28098927
[TBL] [Abstract][Full Text] [Related]
10. A critical review on HE4 performance in endometrial cancer: where are we now?
Angioli R; Miranda A; Aloisi A; Montera R; Capriglione S; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2014 Feb; 35(2):881-7. PubMed ID: 24068567
[TBL] [Abstract][Full Text] [Related]
11. Expression of HE4 in Endometrial Cancer and Its Clinical Significance.
Li X; Gao Y; Tan M; Zhuang H; Gao J; Hu Z; Wang H; Zhu L; Liu J; Lin B
Biomed Res Int; 2015; 2015():437468. PubMed ID: 26539494
[TBL] [Abstract][Full Text] [Related]
12. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
13. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
14. Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital.
Prueksaritanond N; Cheanpracha P; Yanaranop M
Asian Pac J Cancer Prev; 2016; 17(3):1489-92. PubMed ID: 27039795
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumour cells may add value in endometrial cancer management.
Ni T; Sun X; Shan B; Wang J; Liu Y; Gu SL; Wang YD
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():1-4. PubMed ID: 27756035
[TBL] [Abstract][Full Text] [Related]
16. HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A
Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819
[TBL] [Abstract][Full Text] [Related]
17. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.
Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F
Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.
Minar L; Klabenesova I; Jandakova E; Zlamal F; Bienertova-Vasku J
J Obstet Gynaecol Res; 2015 Oct; 41(10):1644-52. PubMed ID: 26223178
[TBL] [Abstract][Full Text] [Related]
20. Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.
Presl J; Ovesna P; Novotny Z; Vlasak P; Bouda J; Kostun J; Topolcan O; Kucera R; Bednarikova M; Weinberger V
Anticancer Res; 2017 May; 37(5):2697-2702. PubMed ID: 28476847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
